Effect of HER2/neu expression on survival in non-small-cell lung cancer.
Effect of HER2/neu expression on survival in non-small-cell lung cancer.
复制标题
DOI：
10.3816/clc.2001.n.006
复制
发表时间：
2001-02-01
影响因子：
3.6
通讯作者：
Mott, F E
中科院分区：
文献类型：
--
作者：
Korrapati, V;Gaffney, M;Mott, F E
早期非小细胞肺癌（NSCLC）的主要预后因素是肿瘤大小和淋巴结状态。有研究表明，HER 2/neu过表达可能与NSCLC的不良预后有关。我们评估了HER 2/neu过表达对NSCLC患者生存的意义。收集了1987年至1996年期间手术治疗的239例I/II期NSCLC患者的数据。所有患者均未接受辅助化疗或放疗。用p185/HER 2受体抗体对福尔马林固定、石蜡包埋的肿瘤组织样本进行染色。结果报告为阳性（2+，3+）或阴性（0，1+）（A组）。一项单独的分析仅将3+视为阳性（B组）。A组中18%（43/239）和B组中6%（15/239）观察到HER 2/neu过表达。HER 2/neu在支气管肺泡细胞癌和腺癌中表达最高。两组中I期肿瘤的阳性率均高于II期，但仅A组有显著性差异（21% vs. 7%，P = 0.02）。两组的年龄、性别或年级均无差异。在A组中，HER 2/neu过表达肿瘤的复发率为55%，HER 2/neu阴性肿瘤的复发率为31%（P = 0.003）。HER 2/neu阳性肿瘤患者的中位至复发时间为2.9年; HER 2/neu阴性肿瘤患者未达到该时间。HER 2/neu阳性肿瘤患者的中位生存期为3.6年，而HER 2/neu阴性肿瘤患者为5年（P = 0.66）。在B组中，HER 2/neu过表达肿瘤的复发率为60%，阴性肿瘤的复发率为33%（P = 0.036）。HER 2/neu阳性患者的中位复发时间为3.4年，而阴性肿瘤患者的中位复发时间尚未达到。两组的5年生存率没有差异（HER 2/neu阳性组为47%，阴性组为50%，P = 0.66）。
Major prognostic factors for early-stage non-small-cell lung cancer (NSCLC) are tumor size and nodal status. It has been suggested that HER2/neu overexpression may be related to poor prognosis in NSCLC. We evaluated the significance of HER2/neu overexpression on survival in patients with NSCLC. Data were collected on 239 patients treated surgically for stage I/II NSCLC between 1987 and 1996. None of the patients received adjuvant chemotherapy or radiation. Formalin-fixed, paraffin-embedded tumor tissue samples were stained with p185/HER2 receptor antibody. Results were reported as positive (2+, 3+) or negative (0, 1+) (Group A). A separate analysis considered only 3+ as positive (Group B). HER2/neu overexpression was seen in 18% in Group A (43 of 239) and 6% in Group B (15 of 239). HER2/neu overexpression was highest in bronchoalveolar cell carcinoma and adenocarcinoma. More stage I tumors were positive than stage II in both groups, but this was significant only in Group A (21% vs. 7%, P = 0.02). No difference was seen with age, gender, or grade for either group. In Group A, the relapse rate was 55% for HER2/neu-overexpressing tumors and 31% for HER2/neu-negative tumors (P = 0.003). Median time to relapse in patients with HER2/neu-positive tumors was 2.9 years; it was not reached in patients with HER2/neu-negative tumors. Median survival of patients with HER2/neu-positive tumors was 3.6 years compared to 5 years in patients with HER2/neu-negative tumors (P = 0.66). In Group B, the relapse rate was 60% for HER2/neu-overexpressing tumors and 33% for negative tumors (P = 0.036). Median time to relapse was 3.4 years in HER2/neu positive and had not been reached in negative tumors. There was no difference in 5-year survival rates for both groups (47% for HER2/neu positive and 50% for negative, P = 0.66).